logo
Allergens May Make Us Cough and Sneeze by Poking Holes in Airway Cells

Allergens May Make Us Cough and Sneeze by Poking Holes in Airway Cells

The sneezing, itchy eyes and coughing elicited by some allergens are caused by proteins creating holes in airway cells, reports a study published this week in Nature.
The findings challenge scientists' understanding of how allergies are triggered, says Feargal Ryan, who studies host–microbe interactions at Flinders University in Adelaide, Australia. Before this, the mechanism that triggers immune responses to allergens was not really understood. Researchers focused mostly on how a single allergen elicits a reaction, rather than looking for a generalizable mechanism.
The results could also change allergy-treatment strategies, which typically target the allergen directly or downstream immune responses. Now, researchers can start looking for ways to target the hole-creating proteins that are initiating the immune response, Ryan says.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Pore-forming proteins
Researchers based in Beijing, China, identified two proteins in the mould Alternaria alternata, which causes allergic reactions in about 5% of people, that trigger the airway inflammation seen during allergic reactions.
Together, the proteins, called Aeg-S and Aeg-L, create a pore in the membranes of cells lining the nose, throat and lungs. This allows calcium ions to enter the cells and release molecules that alert the immune system to danger. The damage to cell membranes from these pore-forming proteins could be a 'common signal that our body uses to recognize something as an allergen', says co-author Mo Xu, who studies immune responses at Tsinghua University.
To test how the proteins stimulated the immune system, the team treated lung cells with the proteins. Administering the proteins at the same time triggered a similar response as administering an extract of A. alternata, but this response was not seen when the proteins were given one at a time.
The researchers also tested whether the proteins could cause an allergic airway inflammation in mice. Six hours after mice were given the proteins intranasally, the rodents showed immune responses similar to those triggered by exposure to A. alternata.
The team also observed signs that the mice had developed a respiratory allergy, such as increased levels of serum immunoglobulin E (IgE) — an antibody produced in response to allergens — after the mice were given the proteins every three days for two weeks. This response wasn't seen when the proteins were administered separately, or when mice were exposed to genetically modified mould lacking either protein.
Common trigger
The team suspected that other allergens with pore-forming proteins would also induce an immune response. When the researchers exposed mice to pore-forming proteins from the airborne mould Aspergillus niger — an allergen — and the venom of the sea anemone Actinia equina, they observed an immune response similar to that induced by Aeg-S and Aeg-L. They also found that allergic airway inflammation was triggered by pore-forming proteins from the earthworm Eisenia fetida, the king oyster mushroom Pleurotus eryngii, the bacterium Clostridium perfringens and the fungus Laetiporus sulphureus.
The findings suggest that allergens that are unrelated to each other can trigger allergic reactions in the same way, because they have pore-forming proteins that have been conserved by evolution, says Ryan. 'This is a new way of thinking about allergens,' he says. Future treatments could look at whether there's a way to block or inactivate those proteins and stop the reactions, he adds.
Xu says his team are investigating which immune-response pathways are activated after pore-forming proteins damage cell membranes, and whether allergens with proteins that don't form pores, such as those in dust mites or pollens, use the same pathway.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Miniature Neutrino Detector Catches Elusive Particles at Nuclear Reactor
Miniature Neutrino Detector Catches Elusive Particles at Nuclear Reactor

Yahoo

time8 hours ago

  • Yahoo

Miniature Neutrino Detector Catches Elusive Particles at Nuclear Reactor

A relatively small detector caught neutrinos from a nuclear reactor using a technique known as coherent scattering Physicists have caught neutrinos from a nuclear reactor using a device weighing just a few kilograms, orders of magnitude less massive than standard neutrino detectors. The technique opens new ways to stress-test the known laws of physics and to detect the copious neutrinos produced in the hearts of collapsing stars. 'They finally did it,' says Kate Scholberg, a physicist at Duke University in Durham, North Carolina. 'And they have very beautiful result.' The experiment, called CONUS+, is described on 30 July in Nature. Challenging quarry Neutrinos are elementary particles that have no electrical charge and generally don't interact with other matter, making them extraordinarily difficult to detect. Most neutrino experiments catch these elusive particles by observing flashes of light that are generated when a neutrino collides with an electron, proton or neutron. These collisions occur extremely infrequently, so such detectors typically have masses of tonnes or thousands of tonnes to provide enough target material to gather neutrinos in relevant numbers. [Sign up for Today in Science, a free daily newsletter] Scholberg and her collaborators first demonstrated the mini-detector technique in 2017, using it to catch neutrinos produced by an accelerator at Oak Ridge National Laboratory in Tennessee. The Oak Ridge particles have slightly higher energies than those made in reactors. As a result, detecting reactor neutrinos was even more challenging, she says. But lower-energy neutrinos also allow for a more precise test of the standard model of physics. Scholberg's COHERENT detector was the first to exploit a phenomenon called coherent scattering, in which a neutrino 'scatters' off an entire atomic nucleus rather than the atom's constituent particles. Coherent scattering uses the fact that particles of matter can act as waves — and the lower the particles' energy, the longer their wavelength, says Christian Buck, a leader of the CONUS collaboration. If the wavelength of a neutrino is similar to the nucleus's diameter, 'then the neutrino sees the nucleus as one thing. It doesn't see the internal structure', says Buck, who is a physicist at the Max Planck Institute for Nuclear Physics in Heidelberg, Germany. The neutrino doesn't interact with any subatomic particles, but does cause the nucleus to recoil — depositing a tiny amount of energy into the detector. Catching sight of a nucleus Coherent scattering occurs more than 100 times as frequently as the interactions used in other detectors, where the neutrino 'sees' a nucleus as a collection of smaller particles with empty space in between. This higher efficiency means that detectors can be smaller and still spot a similar number of particles in the same time frame. 'Now you can afford to build detectors on the kilogram scale,' Buck says. The downside is that the neutrinos deposit much less energy at the nucleus. The recoil induced on a nucleus by a neutrino is comparable to that produced on a ship by a ping-pong ball, Buck says — and has until recent years has been extremely challenging to measure. The CONUS detector is made of four modules of pure germanium, each weighing 1 kilogram. It operated at a nuclear reactor in Germany from 2018 until that reactor was shut down in 2022. The team then moved the detector, upgraded to CONUS+, to the Leibstadt nuclear power plant in Switzerland. From the new location, the team now reports having seen around 395 collision events in 119 days of operation — consistent with the predictions of the standard model of particle physics. After COHERENT's landmark 2017 result, which was obtained with detectors made of caesium iodide, Scholberg's team repeated the feat with detectors made of argon and of germanium. Separately, last year, two experiments originally designed to hunt for dark matter reported seeing hints of low-energy coherent scattering of neutrinos produced by the Sun. Scholberg says that the standard model makes very clean predictions of the rate of coherent scattering and how it changes with different types of atomic nucleus, making it crucial to compare results from as many detecting materials as possible. And if the technique's sensitivity improves further, coherent scattering could help to push forward the state of the art of solar science. Researchers say that coherent scattering will probably not completely replace any existing technologies for detecting neutrinos. But it can spot all three known types of neutrino (and their corresponding antiparticles) down to low energies, whereas some other techniques can capture only one type. This ability means it could complement massive detectors that aim to pick up neutrinos at higher energies, such as the Hyper-Kamiokande observatory now under construction in Japan. This article is reproduced with permission and was first published on July 30 2025. Solve the daily Crossword

Could a single shot at birth shield kids from HIV for years?
Could a single shot at birth shield kids from HIV for years?

Yahoo

time15 hours ago

  • Yahoo

Could a single shot at birth shield kids from HIV for years?

There's potentially exciting news from a trial conducted in monkeys: A single shot of gene therapy given to newborn monkeys appears to shield them from HIV, the virus that causes AIDS, for at least three years. Of course, studies conducted in animals don't always pan out in humans. But scientists say that if it does, it could save the lives of babies and children still imperiled by HIV. The study authors estimate that more than 100,000 children worldwide (largely in subSaharan Africa) are believed to contract HIV soon after birth, primarily via breastfeeding with an HIV+ mother. "Nearly 300 children are infected with HIV each day," said lead author Dr. Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center in New Orleans. "This approach could help protect newborns in high-risk areas during the most vulnerable period of their lives." His team published its findings July 30 in Nature. It noted that the new work hinges on the notion that in the first few weeks of a primate's life -- humans are primates, too -- the body's immune system is naturally more tolerant of "invaders," including gene therapies. The research focused on a tried-and-true form of HIV-fighting gene therapy. It works by programming cells to continuously produce HIV-fighting antibodies. The gene therapy was piggybacked onto a harmless adeno-associated virus (AAV) to help deliver it to the muscle cells of newborn rhesus macaques. Muscle cells were chosen because they are particularly long-lived, Ardeshir's team explained. The gene therapy instructs these cells to produce broadly neutralizing antibodies, or bNAbs, which are capable of neutralizing multiple strains of HIV. It's not the first time bNAbs have been used in gene therapy to fight HIV. However, in prior trials repeat injections were required to keep the immune system vigilant. In the new trial, "we turn these muscle cells -- which are long-lived -- into micro factories that just keep producing these antibodies," Ardeshir explained. When such an approach is used in older monkeys, however, the animals' robust immune systems turn against the therapy, shutting it down. That didn't happen when Ardeshir's team introduced it during a macaque's first few weeks of life. All of the monkeys who got a single shot of bNAbs therapy soon after birth were shielded from infection with HIV for at least three years, with no need for a booster. Tulane researchers said that's roughly the equivalent of a treatment that could ward off HIV in humans deep into adolescence. If the gene therapy was delivered even a bit later -- 8 to 12 weeks after birth -- the young monkey's more developed immune system swung into action to fight it, eroding its effectiveness. Giving the shot soon after birth seemed key, Ardeshir said. "This is a one-and-done treatment that fits the critical time when these mothers with HIV in resource-limited areas are most likely to see a doctor," he noted in a Tulane news release. "As long as the treatment is delivered close to birth, the baby's immune system will accept it and believe it's part of itself." Will it work in human babies? That's not entirely clear, since it's possible infants might be less amenable than monkeys to therapies that are delivered via AAV, the team said. The monkey trial also used only one strain of simian-human immunodeficiency virus, which is similar in some ways to HIV but may not reflect the variety of circulating strains of HIV strains. Still, the research team is hopeful. Giving families a one-shot preventive tool to protect their children would be especially useful in areas where access to repeat medical treatments can be tough, the researchers said. "Nothing like this was possible to achieve even 10 years ago," Ardeshir said. "This was a huge result, and now we have all the ingredients to take on HIV." More information Find out more about HIV and AIDS at the U.S. Centers for Disease Control and Prevention (CDC). SOURCE: Tulane University, news release, July 30, 2025 Copyright © 2025 HealthDay. All rights reserved.

Could a single shot at birth shield kids from HIV for years?
Could a single shot at birth shield kids from HIV for years?

UPI

time21 hours ago

  • UPI

Could a single shot at birth shield kids from HIV for years?

There's potentially exciting news from a trial conducted in monkeys: A single shot of gene therapy given to newborn monkeys appears to shield them from HIV, the virus that causes AIDS, for at least three years. Of course, studies conducted in animals don't always pan out in humans. But scientists say that if it does, it could save the lives of babies and children still imperiled by HIV. The study authors estimate that more than 100,000 children worldwide (largely in subSaharan Africa) are believed to contract HIV soon after birth, primarily via breastfeeding with an HIV+ mother. "Nearly 300 children are infected with HIV each day," said lead author Dr. Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center in New Orleans. "This approach could help protect newborns in high-risk areas during the most vulnerable period of their lives." His team published its findings July 30 in Nature. It noted that the new work hinges on the notion that in the first few weeks of a primate's life -- humans are primates, too -- the body's immune system is naturally more tolerant of "invaders," including gene therapies. The research focused on a tried-and-true form of HIV-fighting gene therapy. It works by programming cells to continuously produce HIV-fighting antibodies. The gene therapy was piggybacked onto a harmless adeno-associated virus (AAV) to help deliver it to the muscle cells of newborn rhesus macaques. Muscle cells were chosen because they are particularly long-lived, Ardeshir's team explained. The gene therapy instructs these cells to produce broadly neutralizing antibodies, or bNAbs, which are capable of neutralizing multiple strains of HIV. It's not the first time bNAbs have been used in gene therapy to fight HIV. However, in prior trials repeat injections were required to keep the immune system vigilant. In the new trial, "we turn these muscle cells -- which are long-lived -- into micro factories that just keep producing these antibodies," Ardeshir explained. When such an approach is used in older monkeys, however, the animals' robust immune systems turn against the therapy, shutting it down. That didn't happen when Ardeshir's team introduced it during a macaque's first few weeks of life. All of the monkeys who got a single shot of bNAbs therapy soon after birth were shielded from infection with HIV for at least three years, with no need for a booster. Tulane researchers said that's roughly the equivalent of a treatment that could ward off HIV in humans deep into adolescence. If the gene therapy was delivered even a bit later -- 8 to 12 weeks after birth -- the young monkey's more developed immune system swung into action to fight it, eroding its effectiveness. Giving the shot soon after birth seemed key, Ardeshir said. "This is a one-and-done treatment that fits the critical time when these mothers with HIV in resource-limited areas are most likely to see a doctor," he noted in a Tulane news release. "As long as the treatment is delivered close to birth, the baby's immune system will accept it and believe it's part of itself." Will it work in human babies? That's not entirely clear, since it's possible infants might be less amenable than monkeys to therapies that are delivered via AAV, the team said. The monkey trial also used only one strain of simian-human immunodeficiency virus, which is similar in some ways to HIV but may not reflect the variety of circulating strains of HIV strains. Still, the research team is hopeful. Giving families a one-shot preventive tool to protect their children would be especially useful in areas where access to repeat medical treatments can be tough, the researchers said. "Nothing like this was possible to achieve even 10 years ago," Ardeshir said. "This was a huge result, and now we have all the ingredients to take on HIV." More information Find out more about HIV and AIDS at the U.S. Centers for Disease Control and Prevention (CDC). SOURCE: Tulane University, news release, July 30, 2025 Copyright © 2025 HealthDay. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store